Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 9/2018

28.06.2018 | Original Article

Extremely and pandrug-resistant bacteria extra-deaths: myth or reality?

verfasst von: Cédric Abat, Pierre-Edouard Fournier, Marie-Thérèse Jimeno, Jean-Marc Rolain, Didier Raoult

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

In 2009, the European Centre for Disease Prevention and Control (ECDC) estimated that multidrug-resistant (MDR) bacterial infections were responsible for 25,000 extra-deaths per year. In 2015, another report estimated that 12,500 extra-deaths were attributable to MDR bacteria every year in France. Recently, the United Nations claimed that resistance to antimicrobials was a global scourge, forecasting 10 million deaths in 2050. Surprisingly, our antibiotic resistance surveillance system in Marseille, France, did not allowed us to observe similar trends. We herein compared our data on extremely drug-resistant (XDR)/pandrug-resistant (PDR) patient extra-deaths to evaluations and predictions from these reports. First, we retrospectively collect and analyze antibiotic resistance data produced by our settings between November 2009 and March 2015 to look for 30-day deaths attributable to XDR/PDR strains belonging to 11 bacterial species/genus. In parallel, we performed a PubMed literature search to look for articles published prior to July 2016 and describing human deaths due to PDR strains. Overall, 35,723 patients were infected by at least one bacterial species/genus of interest and 85 by XDR/PDR strains. Of these patients, only one death was attributable to a XDR bacterial infection in a patient with strong comorbidities and two consecutive septic shocks. Our literature review shows that only four articles described human deaths due to PDR bacteria. All together, these data allowed us to conclude that there is a large discrepancy between the real count of deaths attributable to XDR/PDR bacteria and alarmist predictions.
Literatur
2.
6.
Zurück zum Zitat Abat C, Chaudet H, Colson P, Rolain J-M, Raoult D (2015) Real-time microbiology laboratory surveillance system to detect abnormal events and emerging infections, Marseille, France. Emerg Infect Dis 21:1302–1310CrossRefPubMedPubMedCentral Abat C, Chaudet H, Colson P, Rolain J-M, Raoult D (2015) Real-time microbiology laboratory surveillance system to detect abnormal events and emerging infections, Marseille, France. Emerg Infect Dis 21:1302–1310CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Dobbin C, Maley M, Harkness J, Benn R, Malouf M, Glanville A et al (2004) The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 56:277–282CrossRefPubMed Dobbin C, Maley M, Harkness J, Benn R, Malouf M, Glanville A et al (2004) The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 56:277–282CrossRefPubMed
8.
Zurück zum Zitat Hadjiliadis D, Steele MP, Chaparro C, Singer LG, Waddell TK, Hutcheon MA et al (2007) Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 26:834–838CrossRefPubMed Hadjiliadis D, Steele MP, Chaparro C, Singer LG, Waddell TK, Hutcheon MA et al (2007) Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant 26:834–838CrossRefPubMed
9.
Zurück zum Zitat Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A (2008) Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 32:450–454CrossRefPubMed Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A (2008) Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 32:450–454CrossRefPubMed
10.
Zurück zum Zitat Elemam A, Rahimian J, Mandell W (2009) Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 49:271–274CrossRefPubMed Elemam A, Rahimian J, Mandell W (2009) Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 49:271–274CrossRefPubMed
11.
Zurück zum Zitat Rolain J-M, Abat C, Jimeno M-T, Fournier P-E, Raoult D (2016) Do we need new antibiotics? Clin Microbiol Infect 22:408–415CrossRefPubMed Rolain J-M, Abat C, Jimeno M-T, Fournier P-E, Raoult D (2016) Do we need new antibiotics? Clin Microbiol Infect 22:408–415CrossRefPubMed
12.
Zurück zum Zitat Ramírez-Estrada S, Borgatta B, Rello J (2016) Pseudomonas aeruginosa ventilator-associated pneumonia management. Infect Drug Resist 9:7–18PubMedPubMedCentral Ramírez-Estrada S, Borgatta B, Rello J (2016) Pseudomonas aeruginosa ventilator-associated pneumonia management. Infect Drug Resist 9:7–18PubMedPubMedCentral
13.
Zurück zum Zitat Bodey GP, Jadeja L, Elting L (1985) Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 145:1621–1629CrossRefPubMed Bodey GP, Jadeja L, Elting L (1985) Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 145:1621–1629CrossRefPubMed
16.
Zurück zum Zitat Abat C, Rolain J-M, Dubourg G, Fournier P-E, Chaudet H, Raoult D (2017) Evaluating the clinical burden and mortality attributable to antibiotic resistance: the disparity of empirical data and simple model estimations. Clin Infect Dis 65:S58–S63CrossRefPubMed Abat C, Rolain J-M, Dubourg G, Fournier P-E, Chaudet H, Raoult D (2017) Evaluating the clinical burden and mortality attributable to antibiotic resistance: the disparity of empirical data and simple model estimations. Clin Infect Dis 65:S58–S63CrossRefPubMed
17.
Zurück zum Zitat de Kraker MEA, Stewardson AJ, Harbarth S (2016) Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med 29(13):e1002184CrossRef de Kraker MEA, Stewardson AJ, Harbarth S (2016) Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med 29(13):e1002184CrossRef
18.
Zurück zum Zitat Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ (2014) Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20:1170–1175CrossRefPubMedPubMedCentral Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ (2014) Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20:1170–1175CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Andersson DI, Hughes D (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8:260–271CrossRefPubMed Andersson DI, Hughes D (2010) Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 8:260–271CrossRefPubMed
20.
Zurück zum Zitat Moran NA (2002) Microbial minimalism: genome reduction in bacterial pathogens. Cell 8(108):583–586CrossRef Moran NA (2002) Microbial minimalism: genome reduction in bacterial pathogens. Cell 8(108):583–586CrossRef
21.
Zurück zum Zitat López-Rojas R, Domínguez-Herrera J, McConnell MJ, Docobo-Peréz F, Smani Y, Fernández-Reyes M et al (2011) Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 203:545–548CrossRefPubMedPubMedCentral López-Rojas R, Domínguez-Herrera J, McConnell MJ, Docobo-Peréz F, Smani Y, Fernández-Reyes M et al (2011) Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 203:545–548CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Hraiech S, Roch A, Lepidi H, Atieh T, Audoly G, Rolain J-M et al (2013) Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia. Antimicrob Agents Chemother 57:5120–5121CrossRefPubMedPubMedCentral Hraiech S, Roch A, Lepidi H, Atieh T, Audoly G, Rolain J-M et al (2013) Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia. Antimicrob Agents Chemother 57:5120–5121CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Levy Hara G, Kanj SS, Pagani L, Abbo L, Endimiani A, Wertheim HFL et al (2016) Ten key points for the appropriate use of antibiotics in hospitalised patients: a consensus from the Antimicrobial Stewardship and Resistance Working Groups of the International Society of Chemotherapy. Int J Antimicrob Agents 48:239–246CrossRefPubMed Levy Hara G, Kanj SS, Pagani L, Abbo L, Endimiani A, Wertheim HFL et al (2016) Ten key points for the appropriate use of antibiotics in hospitalised patients: a consensus from the Antimicrobial Stewardship and Resistance Working Groups of the International Society of Chemotherapy. Int J Antimicrob Agents 48:239–246CrossRefPubMed
24.
Zurück zum Zitat Pulcini C, Mainardi J-L (2014) Antimicrobial stewardship: an international emergency. Clin Microbiol Infect 20:947–948CrossRefPubMed Pulcini C, Mainardi J-L (2014) Antimicrobial stewardship: an international emergency. Clin Microbiol Infect 20:947–948CrossRefPubMed
25.
Zurück zum Zitat Brouqui P, Jouve E, Romain F, Sambuc R, Raoult D (2014) Are infectious disease doctors better at caring for infectious diseases than other specialists? Clin Infect Dis 58:1486–1487CrossRefPubMed Brouqui P, Jouve E, Romain F, Sambuc R, Raoult D (2014) Are infectious disease doctors better at caring for infectious diseases than other specialists? Clin Infect Dis 58:1486–1487CrossRefPubMed
26.
Zurück zum Zitat Brouqui P, Boudjema S, Soto Aladro A, Chabrière E, Florea O, Nguyen H et al (2017) New approaches to prevent healthcare-associated infection. Clin Infect Dis 65:S50–S54CrossRefPubMed Brouqui P, Boudjema S, Soto Aladro A, Chabrière E, Florea O, Nguyen H et al (2017) New approaches to prevent healthcare-associated infection. Clin Infect Dis 65:S50–S54CrossRefPubMed
27.
Zurück zum Zitat Lagier J-C, Aubry C, Delord M, Michelet P, Tissot-Dupont H, Million M et al (2017) From expert protocols to standardized management of infectious diseases. Clin Infect Dis 65:S12–S19CrossRefPubMed Lagier J-C, Aubry C, Delord M, Michelet P, Tissot-Dupont H, Million M et al (2017) From expert protocols to standardized management of infectious diseases. Clin Infect Dis 65:S12–S19CrossRefPubMed
28.
Zurück zum Zitat Lagier JC, Million M, Fournier PE, Brouqui P, Raoult D (2015) Faecal microbiota transplantation for stool decolonization of OXA-48 carbapenemase-producing Klebsiella pneumoniae. J Hosp Infect 90:173–174CrossRefPubMed Lagier JC, Million M, Fournier PE, Brouqui P, Raoult D (2015) Faecal microbiota transplantation for stool decolonization of OXA-48 carbapenemase-producing Klebsiella pneumoniae. J Hosp Infect 90:173–174CrossRefPubMed
29.
Zurück zum Zitat Brouqui P, Aubry C, Million M, Drancourt M, Raoult D (2013) Totally resistant tuberculosis: will antileprosy drugs be helpful? Int J Antimicrob Agents 42:584–585CrossRefPubMed Brouqui P, Aubry C, Million M, Drancourt M, Raoult D (2013) Totally resistant tuberculosis: will antileprosy drugs be helpful? Int J Antimicrob Agents 42:584–585CrossRefPubMed
30.
Zurück zum Zitat Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O et al (2017) Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents 49:98–101CrossRefPubMed Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O et al (2017) Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia. Int J Antimicrob Agents 49:98–101CrossRefPubMed
31.
Zurück zum Zitat Dubourg G, Okdah L, Le Page S, Rolain J-M, Raoult D (2015) In vitro activity of “old antibiotics” against highly resistant Gram-negative bacteria. Int J Antimicrob Agents 46:718–720CrossRefPubMed Dubourg G, Okdah L, Le Page S, Rolain J-M, Raoult D (2015) In vitro activity of “old antibiotics” against highly resistant Gram-negative bacteria. Int J Antimicrob Agents 46:718–720CrossRefPubMed
32.
Zurück zum Zitat Abat C, Raoult D, Rolain J-M (2018) Are we living in an antibiotic resistance nightmare? Clin Microbiol Infect XXX:1–2 Abat C, Raoult D, Rolain J-M (2018) Are we living in an antibiotic resistance nightmare? Clin Microbiol Infect XXX:1–2
33.
Zurück zum Zitat McGann P, Snesrud E, Maybank R, Corey B, Ong AC, Clifford R et al (2016) Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the United States. Antimicrob Agents Chemother 60:4420–4421CrossRefPubMedPubMedCentral McGann P, Snesrud E, Maybank R, Corey B, Ong AC, Clifford R et al (2016) Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the United States. Antimicrob Agents Chemother 60:4420–4421CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281CrossRefPubMed Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG et al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268–281CrossRefPubMed
Metadaten
Titel
Extremely and pandrug-resistant bacteria extra-deaths: myth or reality?
verfasst von
Cédric Abat
Pierre-Edouard Fournier
Marie-Thérèse Jimeno
Jean-Marc Rolain
Didier Raoult
Publikationsdatum
28.06.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 9/2018
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-018-3300-0

Weitere Artikel der Ausgabe 9/2018

European Journal of Clinical Microbiology & Infectious Diseases 9/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.